Comparative Pharmacology
Head-to-head clinical analysis: POSFREA versus TERAZOL 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSFREA versus TERAZOL 7.
POSFREA vs TERAZOL 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Terconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This disruption increases membrane permeability and leads to fungal cell death.
IV 4 mg/kg once daily; infused over 90 minutes.
Intravaginal: One full applicator (approximately 5 g of cream containing 40 mg of terconazole) inserted vaginally once daily at bedtime for 7 consecutive days.
None Documented
None Documented
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 7-10 hours; clinically, it allows for once-daily vaginal application, but systemic accumulation is minimal with vaginal dosing.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Primarily fecal (approximately 60%) as unchanged drug and metabolites; renal excretion accounts for about 20% (mostly metabolites).
Category C
Category C
Azole Antifungal
Azole Antifungal